'Breakthrough' status granted to Aimmune's peanut allergy drug
This article was originally published in Scrip
Executive Summary
The FDA has granted breakthrough therapy designation (BTD) to Aimmune Therapeutics' investigational oral immunotherapy for peanut allergy, known as AR101.